Letter by Costantine et al Regarding Article, "Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia"

Circulation. 2022 Jan 25;145(4):e115-e116. doi: 10.1161/CIRCULATIONAHA.121.056728. Epub 2022 Jan 24.

Authors

Maged M Costantine¹, Kirsten Lawrence-Cleary², Georges Saade³, Ronald J Wapner⁴

Affiliations

¹ Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus (M.M.C.).
² Department of Obstetrics and Gynecology, Yale University, New Haven, CT (K.L.-C.).
³ Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston (G.S.).
⁴ Department of Obstetrics and Gynecology, Columbia University, New York, NY (R.J.W.).

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Pravastatin / therapeutic use
Pre-Eclampsia* / diagnosis
Pre-Eclampsia* / drug therapy
Pre-Eclampsia* / epidemiology
Pregnancy

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pravastatin

Grants and funding